Drugs / SM08502
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05084859 | Nov 2021 → Oct 2022 | castration-resistant prostate carcinoma, colorectal cancer, non-small cell lung carcinoma | Biosplice Therapeutics, Inc. | Terminated | No outcome recorded Stop: Business |
| Phase 1 | NCT03355066 | Nov 2017 → Nov 2022 | cancer | Biosplice Therapeutics, Inc. | Terminated | No outcome recorded Stop: Business |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SM08502 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03355066 ↗ |
| Action | Inhibit | “potent inhibition of CDC-like kinase (CLK) activity” PMID 31560935 ↗ Sep 2019 |
| Modality | Small molecule | “SM08502, a novel small molecule in clinical development for the treatment of solid tumors” PMID 31560935 ↗ Sep 2019 |
| Route | Oral | “SM08502 tablets to be administered orally.” NCT03355066 ↗ |